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Abstract 
 
The term frontotemporal dementia (FTD) describes a clinically, genetically and pathologically 
diverse group of neurodegenerative disorders. Symptoms of FTD can present in individuals 
in their twenties through to their nineties, but the mean age at onset is in the sixth decade. 
The most common presentation is with a change in personality and impaired social conduct 
(behavioural variant FTD). Less frequently patients present with language problems (primary 
progressive aphasia). Both of these groups of patients can develop motor features 
consistent with either motor neuron disease (usually the amyotrophic lateral sclerosis 
variant) or parkinsonism (most commonly a progressive supranuclear palsy or corticobasal 
syndrome). In about a third of cases FTD is familial, with mutations in the progranulin, 
microtubule-associated protein tau and chromosome 9 open reading frame 72 genes being 
the major causes. Mutations in a number of other genes including TANK-binding kinase 1 
are rare causes of familial FTD. This review aims to clarify the often confusing terminology of 
FTD, and outline the various clinical features and diagnostic criteria of sporadic and familial 
FTD syndromes. It will also discuss the current major challenges in FTD research and 
clinical practice, and potential areas for future research. 
Page 2 of 67Journal of Neurochemistry
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
3 
 
 
Introduction 
Frontotemporal dementia (FTD) is a clinically and pathologically diverse group of 
progressive neurodegenerative disorders leading to changes in behaviour, social conduct, 
language or speech, due to atrophy of the frontal or anterior temporal lobes of the brain (or 
both). Although it occurs less frequently than Alzheimer’s disease (AD), FTD is a common 
cause of young onset dementia, often affecting individuals below the age of 65 years. 
However, it also affects older individuals, and may be under-diagnosed due to individuals 
being misdiagnosed with AD or other types of dementia (Onyike & Diehl-Schmid 2013). The 
majority of cases have no known cause (‘sporadic’ FTD), but approximately a third is familial, 
secondary to autosomal dominant mutations in one of several FTD-associated genes. There 
are two main clinical subtypes found in patients presenting with FTD: behavioural variant 
FTD (bvFTD), which primarily affects behaviour and social interaction, and primary 
progressive aphasia (PPA), which causes progressive impairment of speech and language. 
Both sporadic and familial FTD patients can also develop concurrent motor neuron disease 
(MND) (Devenney et al. 2015), or an atypical parkinsonian disorder such as corticobasal 
syndrome (CBS) or a progressive supranuclear palsy syndrome (PSPS) (Espay & Litvan 
2011, Kertesz et al. 2011, Park & Chung 2013).  
 
Despite a wealth of studies on FTD, much remains unknown about the disease, including the 
cause of the sporadic form. This is partly due to the heterogeneity of clinical presentation, 
age at disease onset and speed of progression. In addition there is a wide diversity of 
underlying neuropathology in patients with similar clinical presentations, and lack of 
clinicopathological correlation in the majority of patients. The overlap with other neurological 
syndromes makes the disease even more complex. In this review we aim to clarify the 
terminology of FTD, outline the various clinical features and diagnostic criteria of sporadic 
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and familial FTD syndromes and discuss the current major challenges in FTD research and 
clinical practice. We also outline potential areas for future research. 
 Terminology 
Frontotemporal dementia and frontotemporal lobar degeneration 
The terminology of FTD can be confusing, and has evolved significantly since the first 
description of a patient with progressive language disturbance and left superior temporal 
gyrus atrophy by Arnold Pick in 1892 (Pick 1892).  Histopathological presence of argyrophilic 
globular neuronal cytoplasmic inclusions (later termed Pick bodies) was actually described 
not by Pick but by Alois Alzheimer in 1911 (Alzheimer 1911) and the concept of FTD as 
‘Pick’s disease’ by a Dutch group in 1925 (Gans 1925) and by a German group in 1926 
(Onari & Spatz 1926). By 1956 it had become evident that true Pick’s pathology was 
underlying only around 20% of clinical FTD cases (Escourolle 1958) and subsequent studies 
confirmed that there were multiple other pathologies associated with atrophy of the frontal 
and/or temporal lobes in patients with the clinical syndrome of FTD (Brun 1987, Mann et al. 
1993). The historical term for bvFTD, Pick’s disease, is now reserved for cases of FTD with 
Pick type pathology. The term ‘frontotemporal lobar degeneration’ (FTLD) was therefore 
designated to describe a heterogeneous group of neurodegenerative diseases characterized 
by selective frontal and/or temporal lobe atrophy (Neary et al. 1998), and who have non-
Alzheimer’s disease neuropathology (Lashley et al. 2015).   
Behavioral and language variants 
It is now well recognized that there are two main initial clinical presentations seen in patients 
with FTD: bvFTD describes those who develop progressive behavioral change, inappropriate 
social conduct and executive dysfunction, and PPA those who have progressive language 
decline and speech difficulties. There are three variants of PPA: semantic variant PPA 
(svPPA) leading to fluent speech with anomia, impaired single word comprehension and 
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surface dyslexia, due to loss of semantic memory, nonfluent (or agrammatic) variant PPA 
(nfvPPA), leading to effortful speech production with agrammatism, apraxia of speech, and 
impaired sentence comprehension, and logopenic variant PPA (lvPPA) leading to word-
finding pauses and impaired sentence repetition (Gorno-Tempini et al. 2011).  LvPPA is 
mostly associated with AD pathology and is therefore not always included within the FTD 
spectrum, although in a minority of cases it can be associated with FTLD pathology (Lashley 
et al. 2015).  
 
FTD is now used as an umbrella term to describe the overall group of clinical syndromes, 
although has previously been used to just mean the progressive behavioural syndrome now 
called bvFTD (Neary et al. 2005). Other terms used previously for this include frontal lobe 
dementia (Lund and Manchester Groups 1994) and frontal variant FTD. Evolution of PPA 
terminology has been more tortuous. Despite Pick’s original FTD case being a patient with 
language difficulties (Pick 1892) and reports of a variant of FTD with predominant language 
or speech decline published in the early 20th century, explicit description and widespread 
acceptance of a language-led variant of FTD remained elusive until the 1970s. In 1975 
Warrington characterized the presentation of patients with selective deficits in semantic 
memory (Warrington 1975), leading to the later description of semantic dementia (Snowden 
et al. 1989, Hodges et al. 1992). Mesulam also described a slowly progressive selective 
aphasia (Mesulam 1982), later labelling this syndrome as PPA (Mesulam 1987). In an early 
consensus document of diagnostic criteria for behavioral and language variants of FTD, PPA 
was initially split into a fluent subtype (semantic dementia) and a non-fluent subtype 
(progressive nonfluent aphasia, PNFA) (Neary et al. 1998). However, another subtype of 
PPA was subsequently recognized, called logopenic aphasia (LPA) or the 
logopenic/phonological variant of PPA (Gorno-Tempini et al. 2004, Gorno-Tempini et al. 
2008), and this was subsumed into the most recent consensus diagnostic criteria for PPA 
(Gorno-Tempini et al. 2011) which recognizes three variants: nfvPPA, svPPA and lvPPA. 
The nosology of the FTD spectrum is not entirely resolved and several studies of PPA have 
Page 5 of 67 Journal of Neurochemistry
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
6 
 
identified a group of patients that do not fit criteria for any of the three described variants 
(Sajjadi et al. 2012, Wicklund et al. 2014, Sajjadi et al. 2014).  
Overlap syndromes  
In patients with overlap syndromes of FTD with MND, PSPS or CBS, behavioural and 
cognitive symptoms can develop before, after or simultaneously with motor symptoms 
(Kertesz et al. 2011, Park & Chung 2013, Siuda et al. 2014, Devenney et al. 2015). In clinical 
practice, there is often controversy or indecision about what diagnosis to give, or whether to 
revise the diagnosis when new symptoms appear, to capture this development of a new 
mixed phenotype. For example, a patient presenting with behavioral changes consistent with 
bvFTD who later develops falls, supranuclear gaze palsy and axial rigidity, may have their 
diagnosis changed to PSPS. Similarly, a patient with initial language dysfunction 
characterized by effortful and agrammatic speech, who is first diagnosed with nfvPPA, but 
later develops asymmetric limb apraxia, rigidity and myoclonus, may be later rediagnosed 
with CBS. In our experience this changing of the diagnosis can be confusing for patients and 
their families (‘was the initial diagnosis wrong?’), and from a research point of view can lead 
to loss of important phenotypic information (e.g. in pathological or genetic studies it may be 
important to distinguish between PSPS cases who develop PPA and those who develop 
bvFTD). We would advocate the use of overlap terms such as PPA-CBS or FTD-PSPS to 
help clarify such confusion, as has been done with MND: patients with FTD who later 
develop MND are usually diagnosed with FTD-MND (or FTD-ALS), and those with initial 
MND and symptoms that later fit criteria for bvFTD or PPA are labelled as MND-FTD (or 
ALS-FTD). However, overlap of these disorders can be variable and one unresolved 
dilemma is how to classify patients that do not quite fulfill criteria for a particular disorder but 
have mild features. Although around 10-15% of patients with FTD develop MND (Lomen-
Hoerth et al. 2002, Burrell et al. 2011) there is an even higher prevalence of ‘subclinical’ 
evidence of MND, with electromyogram (EMG) evidence of MND or subtle MND-like clinical 
signs, such as fasciculations, in 60% of FTD patients (Lomen-Hoerth et al. 2002). 
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Conversely, whilst 10-20% of MND patients meet diagnostic criteria for FTD, at least fifty 
percent of patients presenting with MND develop cognitive or behavioural impairment, 
termed MNDci (or ALSci) and MNDbi (or ALSbi) (Strong et al., 2009). Of the various MND 
phenotypes seen in FTD patients, the majority usually develop the ALS variant, but lower 
motor neuron (primary muscular atrophy) or upper motor neuron (primary lateral sclerosis) 
phenotypes are also seen rarely (Devenney et al. 2015). As with MND, patients with FTD 
may develop parkinsonian features (bradykinesia, rigidity, tremor and/or postural instability) 
not fully consistent with a particular clinical syndrome such as PSPS or CBS, and are often 
diagnosed with FTD with parkinsonism (FTDP). Parkinsonism is seen in around 20% of 
patients, although a larger proportion may eventually develop this in end-stage disease 
(Park & Chung 2013). One large study of 364 FTD cases (35 with pathological confirmation), 
demonstrated the presence of parkinsonism as an early feature in 16% (18% of bvFTD, 14% 
of nfvPPA and 11% of svPPA) (Seelaar et al. 2008). Very rarely, patients develop FTD, MND 
and parkinsonism, including some patients with an underlying C9ORF72 expansion mutation 
(Coon et al. 2011, Boeve et al. 2012, Mahoney et al. 2012, Snowden et al. 2012, O'Dowd et 
al. 2012).  
 
Sporadic versus familial FTD 
Currently, the only confirmed risk factors for FTD are mutations in certain genes. Between 
30 and 50% of patients report a positive family history of FTD in at least one family member 
and a clearly autosomal dominant inheritance pattern is seen in 10-15% of patients 
(Goldman et al. 2005, Rohrer et al. 2009a). BvFTD is significantly more heritable than PPA, 
with nfvPPA being much more likely to be familial than svPPA (Rohrer et al. 2009a). CBS 
can be familial in some cases, and PSP is only very rarely familial. Estimates of heritability of 
FTD-MND vary widely between studies and it remains unclear how many cases are genetic. 
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Mutations in three genes account for the majority of familial FTD, predominantly through 
autosomal dominant inheritance: progranulin (GRN) (Baker et al. 2006, Cruts et al. 2006), 
microtubule-associated protein tau (MAPT) (Wilhelmsen et al. 1994, Hutton et al. 1998) and 
the chromosome 9 open reading frame 72 (C9ORF72) (DeJesus-Hernandez et al. 2011, 
Renton et al. 2011). More recently, mutations in TRAF family member-associated NF-kappa-
B activator (TANK)-binding kinase 1 (TBK1) have been identified in association with familial 
FTD (Freischmidt et al. 2015, Gijselinck et al. 2015, Le Ber et al. 2015, Pottier et al. 2015). 
Small numbers of patients possess mutations in other rare, FTD-associated genes. 
Mutations in valosin containing protein (VCP)-1 are usually associated with a multisystem 
proteinopathy manifesting as inclusion body myopathy and Paget’s disease of the bone 
(IBMPFD) (Watts et al. 2004), and mutations in charged multivesicular body protein 2B 
(CHMP2B) (Skibinski et al. 2005) are found mainly in a Danish cohort. Rare genetic causes 
of FTD include transactive response DNA binding protein-43 (TARDBP) (Synofzik et al. 
2014), ubiquilin 2 (UBQLN2) (Gellera et al. 2013), p62/sequestome1 (SQSTM1) (Rubino et 
al. 2012, Le Ber et al. 2013, Miller et al. 2015), fused in sarcoma (FUS) (Kwiatkowski et al. 
2009, Vance et al. 2009), dynactin-1 (DCTN1), associated with Perry syndrome (Munch et 
al. 2005) and coiled-coil-helix-coiled-coil-helix domain containing 10 (CHCHD10) (Bannwarth 
et al. 2014). Mutations in presenilin 1 (PSEN1) or amyloid precursor protein (APP), both 
associated with familial AD, and prion protein (PRNP), associated with familial prion disease, 
have also been associated with a clinical FTD syndrome (Rohrer & Warren 2011). A small 
proportion of patients (1.2% in one study of 334 patients) (van Blitterswijk et al. 2013) have 
dual mutations, for example the C9ORF72 expansion as well as another mutation in one of 
the other FTD genes e.g. GRN (Lashley et al. 2014). 
 
Clinical syndromes of FTD 
In this section we summarize the clinical features of bvFTD and PPA variants, with reference 
to most recent diagnostic consensus criteria (Rascovsky et al. 2011, Gorno-Tempini et al. 
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2011). Specific features of the various familial FTD phenotypes will be discussed in the later 
section entitled ‘Clinical syndromes of familial FTD’.   
Behavioural variant FTD 
BvFTD presents with progressive decline in social skills, difficulties with planning and higher 
level thinking due to executive dysfunction, and distinct changes in behaviour, with relative 
preservation of other cognitive areas such as episodic memory and visuospatial function in 
the early stages. Patients with a PPA subtype or PSPS/CBS overlap disorder can also 
display similar behavioural features, as discussed below, but by definition they are not 
predominant at initial presentation. Patients with bvFTD often lack insight into their problems, 
and may seem indifferent or annoyed when brought to medical attention as they feel that 
there is nothing the matter with them. It is usually the patients’ relatives or close friends who 
notice that something is wrong, usually due to a breakdown in their relationship with the 
patient or complaints from friends or work colleagues about odd behavior or increasingly 
poor performance at work. Relatives’ reports of the patient having a ‘poor memory’ usually 
refer more to their perception of a change in the patient’s level of personal and social 
functioning rather than true memory problems, and unfortunately can lead to a misdiagnosis 
of AD or repeated misdiagnoses such as ‘stress’, anxiety or depression by the non-
specialist. Careful questioning in clinic, and particularly of the accompanying relative when 
they are alone, will reveal the true nature of cognitive changes and a history of progression 
of symptoms over time, both essential for aiding correct diagnosis.  
 
Behavioural/cognitive symptoms – diagnosis of possible bvFTD 
requires at least 3 of the following symptoms to be fulfilled: 
Examples of specific symptoms 
 
Early behavioural disinhibition ≥ 1 of: 
 
• Socially inappropriate behaviour 
Staring, inappropriate physical contact with strangers, 
inappropriate sexual behaviour, verbal or physical 
aggression 
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• Loss of manners or decorum 
Lack of social etiquette, insensitive or rude comments, 
preference for crass jokes and slapstick humour, 
inappropriate choices of clothing or gifts 
• Impulsive, rash or careless actions 
New gambling behaviour, driving or investing recklessly, 
overspending, gullibility to phishing/internet scams 
 
Early apathy or inertia ≥ 1 of: 
 
• Apathy 
Reduced drive, stops previous hobbies, stops going out, 
reduced bathing or personal care 
• Inertia 
Lack of persistence or completion of an activity, does not 
initiate activities or conversations 
 
Early loss of sympathy or empathy ≥ 1 of: 
 
• Diminished response to other people’s needs and feelings 
Selfish or hurtful comments or actions, inability to 
perceive when someone is upset, embarrassed, or in 
pain, reduced appreciation of sarcasm or sophisticated 
humor 
• Diminished social interest, interrelatedness, or personal warmth 
Emotionally cold or detached, lack of rapport in 
conversation, loss of interest or affection in relationships 
with friends or family members, reduced interest in sex 
 
Early perseverative, stereotyped or compulsive or ritualistic behavior ≥ 1 of: 
 
• Simple repetitive movements  Repetitive rocking, tapping, clapping, or rubbing 
• Complex compulsive or ritualistic behaviours 
Hoarding, strict grooming or walking routines, 
timekeeping and counting, checking or sorting items, 
cleaning or tidying, new obsessions or interests (usually 
spiritual, religious, artistic, or musical) 
• Stereotypy of speech 
Habitual repetition of particular words, sentences or 
topics 
 
Hyperorality and dietary changes ≥ 1 of: 
 
• Altered food preferences 
Sweet tooth (sweets, biscuits, ice cream), 
carbohydrates, or obsessive food fads 
Page 10 of 67Journal of Neurochemistry
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
11 
 
• Binge eating, increased consumption of alcohol or cigarettes 
Cramming food into mouth, overeating or messy eating, 
new addictions to alcohol or smoking 
• Oral exploration or consumption of inedible objects Pica 
 
Neuropsychological profile – all 3 of: 
 
• Deficits in executive tasks 
Vary as per neuropsychological assessment used • Relative sparing of episodic memory 
• Relative sparing of visuospatial skills 
 
Other features of bvFTD (not in diagnostic criteria) 
 
Examples of specific symptoms 
 Loss of insight Lack of awareness of own condition or symptoms 
 Impaired social cognition 
Poor response to social or emotional cues; impaired 
performance on tests of theory of mind or emotion 
recognition 
 Altered sensitivity to pain 
Heightened perception of a non-painful stimulus or 
reduced response to painful stimulus; hypochondriasis 
or overly focusing on mild physical complaints 
 Altered tolerance of temperature 
Inappropriate clothing for the ambient temperature, such 
as wearing multiple coats or blankets 
 Psychotic features 
Delusions (usually somatic or paranoid) and 
hallucinations (usually visual or tactile) 
 
Table 1. Summary of behavioural and cognitive symptoms within the current diagnostic criteria for behavioral variant 
frontotemporal dementia (bvFTD), and other commonly seen features. Table content is adapted from Rascovsky et al. 
(2011) and Warren et al. (2013). To qualify for a diagnosis of possible bvFTD, patients need to have a progressive deterioration 
of behaviour and/or cognition as per observation or history from an informant, and must possess persistent evidence of least 3 
of the 6 main groups of behavioural/cognitive symptoms listed in the pale grey boxes above. The term ‘early’ refers to within 3 
years of initial symptom onset as per Rascovsky et al. (2011). 
 
The most recent diagnostic criteria for bvFTD (Rascovsky et al. 2011) were developed by 
the FTDC (Frontotemporal Dementia Consortium) to summarize more succinctly the key 
features of behavioral change seen in this subtype, while recognizing that other cognitive 
features such as episodic memory can be affected, albeit less commonly. Criteria for a 
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diagnosis of possible bvFTD are displayed in Table 1; patients must attain any three of six 
key clinical features: five behavioural (disinhibition, apathy or inertia, loss of sympathy or 
empathy, stereotyped or compulsive behaviors, or hyperorality) and one cognitive 
(predominant executive dysfunction on neuropsychological assessment). The sensitivity and 
specificity of these diagnostic criteria for correct diagnosis of bvFTD have been reviewed in a 
number of studies with confirmation of FTLD or non-FTLD pathology, which have 
established that the criteria have 85-95% sensitivity and 82% specificity for a diagnosis of 
possible bvFTD and 75-85% sensitivity and 95% specificity for probable bvFTD (Rascovsky 
et al. 2011, Harris et al. 2013b).  
 
There are a number of clinical features, however, which are not part of the Rascovsky 
criteria and yet are relatively common in bvFTD. In particular, virtually all patients with 
bvFTD have impaired social cognition, with reduced ability to use a ‘theory of mind’ to see 
another person’s point of view or imagine their feelings (Kumfor & Piguet 2012). Several 
studies have shown that patients with bvFTD also display significant impairments in emotion 
recognition, even when tested across multiple modalities, and have more difficulty 
recognizing negative emotions (Lavenu et al. 1999, Rosen et al. 2004, Fernandez-Duque & 
Black 2005, Lough et al. 2006).  They also have difficulty in expressing meaningful emotions, 
resulting in ‘emotional blunting’ (Neary et al. 1998, Sturm et al. 2011).  
 
Several groups have observed altered perception of surrounding environmental and internal 
somatosensory stimuli, including changes in tolerance of pain or temperature. Patients with 
bvFTD tend to have blunted perception of pain (Bathgate et al. 2001, Snowden et al. 2001, 
Carlino et al. 2010, Fletcher et al. 2015) and temperature (Ahmed et al. 2015, Fletcher et al. 
2015). In bvFTD patients this can anecdotally manifest as wearing inappropriately heavy 
clothing or blankets in a warm clinic. Others have developed altered perception of sound or 
music (Seeley et al. 2008, Warren & Rohrer 2009, Barquero et al. 2010, Mahoney et al. 
2011, Fletcher et al. 2013), with some patients merely developing heightened sensitivity to 
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noise (Fletcher et al. 2013) and others frank musicophilia (Fletcher et al. 2013) or amusia 
(Barquero et al. 2010). These phenomena suggest that a variety of networks involved in 
sensory input processing and integration may be affected in FTD.   
 
Neuropsychiatric manifestations such as delusions or hallucinations are found in sporadic 
bvFTD and may be the sole presentation in patients with familial bvFTD (particularly those 
with C9ORF72 or GRN mutations, as discussed later). In a review of 751 cases of FTD 
published in 199 publications from 1950-2007, 46 (6%) of patients presented with 
schizophrenia, schizoaffective disorder, bipolar affective disorder, psychotic depression or 
another psychotic disorder; with 98% of these patients presenting aged less than 60 
(Velakoulis et al. 2009). In another large study of patients with a variety of 
neurodegenerative disorders, including bvFTD, nfvPPA, svPPA, AD, PSPS, CBS and ALS, 
28.5% of patients had received a previous psychiatric diagnosis (usually depression), and 
this was much more common in patients who turned out to have bvFTD (50.7%) than 
nfvPPA (11.8%), svPPA (24.4%) or AD (23.1%) (Woolley et al. 2011).  The typical previous 
psychiatric diagnosis in bvFTD patients in this study was schizophrenia or bipolar disorder. 
Young onset apparently sporadic bvFTD cases with FUS pathology have a particularly high 
(up to 50%) rate of psychiatric symptoms. The lack of other cognitive or neurological 
features early on commonly leads to young and older patients with sporadic and familial 
bvFTD being referred to and assessed within a psychiatric or psychogeriatric setting rather 
than in a specialist cognitive neurology or memory clinic (Lanata & Miller 2015). The obvious 
overlap between early bvFTD symptoms (lack of insight, prominent apathy, obsessive or 
compulsive behaviours, inappropriate sexual behaviour, binge-eating, gambling and 
substance misuse, emotional lability or blunting, delusions and hallucinations) and 
psychiatric presentations (depression, obsessive compulsive disorder, bipolar affective 
disorder, and schizophrenia and other psychotic disorders) can initially lead to misdiagnosis 
of a neurodegenerative disease as a psychiatric disorder. Younger patients with ‘later than 
usual’ onset of neuropsychiatric disease, atypical or prominent behavioural features and any 
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suggestion of multiple family members with significant psychiatric disease (for example 
needing long-term or permanent admission to a mental health facility), ‘early onset 
dementia’, AD, FTD or MND, should be carefully assessed with a neurological examination, 
detailed family history and, wherever possible, formal neuropsychology and detailed MRI 
imaging. 
 
Patients with bvFTD classically have preserved episodic memory, at least early on in 
disease, helping differentiation from AD, but this is not always the case.  Patients often have 
deficits in verbal and visual memory on neuropsychological assessment, even if they do not 
report memory problems; their performance is often worsened by poor strategy during 
assessments due to concurrent executive dysfunction and distractibility. However, a 
significant proportion of pathologically confirmed bvFTD cases have presented with a 
predominant amnestic syndrome (Hodges et al. 2004, Graham et al. 2005, Piguet et al. 
2009, Irish et al. 2013), perhaps due to a higher occurrence of hippocampal sclerosis in the 
older age group (Baborie et al. 2011, Balasa et al. 2015) or mixed pathology (Balasa et al. 
2015). This emphasizes the difficulties clinicians face in making a correct diagnosis, 
particularly in later onset cases, despite using currently available consensus criteria. 
 
The requirements for functional decline and neuroimaging abnormalities for diagnosing 
probable bvFTD, compared with previous diagnostic criteria (Neary et al. 1998), are 
particularly useful for excluding patients with a so-called phenocopy syndrome, who may 
have bvFTD-like symptoms but do not have bvFTD. Relatives of patients with phenocopies 
often seem certain that there is progression over time, but most neuropsychological 
assessments tend to dispute this, often showing normal values or mild but stable impairment 
(Hornberger et al. 2009). These patients have no or minimal atrophy on MRI and normal 
nuclear medicine imaging with PET or SPECT scans, and either remain stable or improve 
over time, without significant disruption of function (Davies et al. 2006). Previous diagnostic 
criteria for bvFTD (Neary et al. 1998) potentially allowed phenocopy cases to be falsely 
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diagnosed as having bvFTD, as they presented almost identically on core diagnostic criteria 
(Hornberger et al. 2009), and these cases are notoriously difficult to tell apart, particularly at 
initial assessment. Repeated assessments of functional abilities over a 12 month period 
(Mioshi & Hodges 2009), neuropsychological assessments of executive function (Hornberger 
et al. 2008) and social cognition (Kipps et al. 2009b), and neuroimaging using combined MRI 
and FDG-PET (Kipps et al. 2009a) appeared most helpful in differentiating phenocopy 
syndromes from true bvFTD, hence their incorporation into the revised criteria (Rascovsky et 
al. 2011). One proviso to this is that some patients can occasionally actually have an 
atypical, very slowly progressive form of FTD, with very slow deterioration on repeated 
neuropsychological assessments over at least 15 years, and neuropathological confirmation 
of typical FTLD pathology (Brodtmann et al. 2013), which further confuses the clinical 
picture. 
 
Primary progressive aphasia 
The key clinical characteristic of PPA is progressive and insidious language decline affecting 
at least one of speech production, object naming, syntax, or word comprehension (Gorno-
Tempini et al. 2011).  Other cognitive or behavioural deficits can develop either early on or in 
late disease but must not be the initial and predominant complaint and language must also 
remain the most impaired domain throughout the disease course (Mesulam 1982, Mesulam 
2003). The most recent diagnostic criteria for PPA have specified that three inclusion criteria, 
based on criteria developed by Mesulam (Mesulam 1982, Mesulam 2001, Mesulam 2003), 
must first be fulfilled for its diagnosis (Gorno-Tempini et al. 2011): 1) the most prominent 
clinical feature is difficulty with language; 2) these deficits are the principal cause of impaired 
daily living activities, and 3) aphasia should be the most prominent deficit at symptom onset 
and for the initial phases of the disease. In addition, none of the following criteria should be 
met: 1) the pattern of deficits is better accounted for by other non-degenerative nervous 
system or medical disorders (e.g. tumour or stroke); 2) the cognitive disturbance is better 
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accounted for by a psychiatric diagnosis; 3) there are prominent initial episodic memory, 
visual memory, and visuoperceptual impairments, and 4) there is prominent, initial 
behavioural disturbance. Once these inclusion and exclusion criteria have been satisfied, 
one can go on to sub-diagnose the syndrome as one of three PPA variants (svPPA, nfvPPA 
or lvPPA), as per diagnostic criteria for each variant [see (Gorno-Tempini et al. 2011) for a 
summary]. Clinical diagnosis can be supplemented by information from neuroimaging 
analyses (leading to the more firm category, ‘imaging-supported diagnosis’). If there is a 
clinical diagnosis of PPA (with or without neuroimaging support) and presence of either a 
known pathogenic gene mutation on DNA analysis or specific neurodegenerative pathology 
on histopathological analysis, this leads to a diagnosis of PPA ‘with definite pathology’.  
 
Different language features can be used to differentiate between the three variants and 
these are summarized these in Table 2. However, not all patients clearly fit into a particular 
variant as they present with a number of features from across the spectrum of language 
dysfunction, and previously have been termed as having mixed disease (PPA-M) (Mesulam 
et al. 2009). More recently patients have been diagnosed with ‘PPA-unclassifiable’ (PPA-U) 
and over time the evolving syndrome may or may not become clearer (Harris et al. 2013b), 
although some are associated with a GRN mutation (Rohrer et al. 2010a). There is also a 
syndrome within the nonfluent aphasia spectrum called progressive primary apraxia of 
speech (PPAOS), which progressively affects speech articulation and production due to 
impaired motor programming, but typically patients lack aphasia initially (Josephs et al. 
2012). It can be associated with development of features of PSPS (Rohrer et al. 2010b, 
Josephs et al. 2014) or, less frequently, CBS (Josephs & Duffy 2008, Assal et al. 2012).  
Here we discuss the clinical features of each PPA variant in turn, the language and 
behavioural features that overlap between them and with bvFTD, the presence of other 
common clinical features, and the overlap with other conditions such as PSPS, CBS and 
MND. 
 
Page 16 of 67Journal of Neurochemistry
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
17 
 
Clinical features svPPA nfvPPA lvPPA 
Spontaneous speech 
(fluency; errors; grammar; 
prosody) 
 
Fluent, garrulous and 
circumlocutory; semantic 
errors; intact grammar and 
prosody 
Slow and hesitant, effortful 
+/- apraxic; phonetic 
errors; may be 
agrammatic; aprosodic 
Hesitant; not effortful or 
apraxic; frequent word-
finding pauses and loss of 
train of sentence; intact 
grammar; intact prosody 
Naming Severe anomia with 
semantic paraphasias  
Moderate anomia with 
phonetic errors and 
phonemic paraphasias 
Mild to moderate anomia 
with occasional phonemic 
paraphasias 
Single word comprehension Poor Intact early on, but 
affected later on 
Intact early on, but 
affected later on 
Sentence comprehension Initially preserved, later on 
becomes impaired as word 
comprehension is impaired 
Impaired if grammatically 
complex 
Impaired, especially if long 
Single word repetition Relatively intact Mild to moderately 
impaired if polysyllabic, 
otherwise intact 
Relatively intact 
(compared with sentence 
repetition)  
Sentence repetition Relatively intact Can be effortful; impaired 
if grammatically complex 
Impaired, with length effect 
Reading Surface dyslexia Phonological dyslexia +/- 
phonetic errors on reading 
aloud 
Phonological dyslexia 
Writing Surface dysgraphia Phonological dysgraphia Phonological dysgraphia 
 
Table 2 Summary of clinical features across the syndromes of primary progressive aphasia. svPPA = semantic variant primary 
progressive aphasia; nfvPPA = nonfluent variant primary progressive aphasia; lvPPA = logopenic variant primary progressive 
aphasia. Clinical features are adapted from tables in: Rohrer et al. (2008), Rohrer et al. (2010a), Seelaar et al. (2011), Gorno-
Tempini et al. (2011). 
 
SvPPA 
SvPPA accounts for around 20% of cases of FTD (Johnson et al. 2005). It is a 
predominantly sporadic disorder (Rohrer et al. 2009a) and presents with a mean age of 
onset of 60, with a range of 40-79 years (Hodges et al. 2010), although is likely under-
diagnosed in older people, particularly as the semantic memory deficits can develop 
insidiously and are usually well-masked by the perception of fluent speech, and use of 
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commonly-used empty speech terms such as ‘thing’ (Fletcher & Warren 2011, Hsieh et al. 
2012). It is associated with bilateral but markedly asymmetrical anterior temporal lobe 
atrophy at presentation, particularly affecting the inferior and middle temporal gyri, but also 
the anterior hippocampus and amygdala (Hodges et al. 1992, Mummery et al. 1999, 
Mummery et al. 2000, Whitwell et al. 2005, Rohrer et al. 2009b). The majority of patients 
present with predominant left temporal lobe atrophy, which leads to the classical language 
disorder of svPPA, characterized by early loss of semantic memory and resultant language 
dysfunction (Snowden et al. 1989, Hodges et al. 1992).  Less frequently patients present 
with predominant right temporal lobe atrophy at onset, often called right temporal lobe 
atrophy (RTLA) FTD or ‘right SD’ cases (Evans et al. 1995, Thompson et al. 2003, Chan et 
al. 2009). The language impairment in svPPA initially manifests as reduced semantic 
knowledge for words, objects and concepts, which affects spoken and written language 
through development of a reduced vocabulary and resultant anomia (Warrington 1975). As 
atrophy worsens and extends across to the right temporal lobe and to the inferior frontal 
lobe, insula, and more posterior left temporal lobe (Seeley et al. 2005, Brambati et al. 2009), 
it impairs semantic function across multiple modalities, leading to associative agnosia for 
visual, auditory, (Bozeat et al. 2000, Goll et al. 2010), tactile (Coccia et al. 2004), olfactory 
(Rami et al. 2007) and gustatory (Piwnica-Worms et al. 2010) stimuli. Patients lose their 
grasp for increasingly imprecise or broad semantic terms and concepts, with responses to 
stimuli becoming more general (e.g. ‘poodle’‘dog’ ‘animal’ ‘don’t know’) over time.   
 
Patients with svPPA generally report word-finding difficulties, which may start off as being 
only for specialist, low frequency (rarely used) words (such as names of flowers for a 
gardener, or facial anatomical terms for a dentist). This worsens to affect commonly used 
words. Patients may ask relatives to explain the meaning of a word someone has said or 
that they have read (Fletcher & Warren 2011, Warren et al. 2013), which at first is usually an 
unusual word, such as ‘orangutan’. Relatives may report the patient does not seem to 
understand what is being said to them, or ‘appears deaf’, asking for instructions to be 
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repeated several times (Rohrer et al. 2008). Clinically, the language dysfunction in svPPA is 
characterized by fluent speech, which is often garrulous or difficult to interrupt but has 
frequent circumlocutions (e.g. ‘thing’ or ‘whatsit’), circumlocutory phrases (imprecise phrases 
that contain vague descriptions or explanations of the word aimed for, e.g. ‘the thing with the 
tail that you ride’ for ‘horse’) and semantic paraphasias (similar but incorrect words often 
from within the same category, .e.g. ‘cat’ for ‘dog’), used by the patient to work around their 
lack of vocabulary (Hodges & Patterson 2007). There can be brief hesitations during word-
finding moments, but overall the speech is much more fluent than the effortful speech in 
nfvPPA or speech with significant pauses in lvPPA. On assessment, patients have anomia 
on confrontation naming tasks (which may appear subtle without detailed probing by a full 
neuropsychological assessment), and impaired comprehension of the meaning of single 
words, particularly on low-frequency items such as ‘monocle’. Later on, there is anomia and 
impaired comprehension of pictures, sounds, smells and tastes. Patients often have 
difficulties with reading and writing, particularly with irregularly spelt words, leading to the 
phenomenon of a surface dyslexia or surface dysgraphia (Warrington 1975, Baxter & 
Warrington 1987). For example, patients will pronounce ‘sew’ as ‘soo’ or ‘yacht as ‘yatched’, 
as they have lost semantic knowledge of the word meaning (and hence the atypical rule for 
how it should be pronounced), relying on sounding out the word as written using superficial 
rules only (Rohrer et al. 2008). Other cognitive domains are usually unaffected, including 
episodic and topographical memory, visuoperceptual function, praxis, calculation, and non-
verbal executive function (Warrington 1975, Gordon et al. 2010, Cipolotti & Maguire 2003). 
Other aspects of language such as speech articulation and prosody, and repetition of 
spoken words and phrases are also usually preserved. Grammar is intact, although as 
vocabulary declines, grammar can sound abnormal, due to use of ‘paragrammatic’, 
circumlocutory phrases and broad classes of terms, which disrupt the normal flow of the 
sentence (Gorno-Tempini et al. 2011).  
 
Page 19 of 67 Journal of Neurochemistry
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
20 
 
Patients with typical svPPA evolve over time (due to spread of disease) to develop 
behavioural changes, which can make it difficult to differentiate these patients from bvFTD 
patients clinically if presenting late in the disease. However, behavioural changes particularly 
found in typical svPPA include obsessionality, mental rigidity, narrowed interests (often 
affecting eating behavior, daily routines and fixations on specific activities e.g. jigsaw 
puzzles) (Snowden et al. 2001, Thompson et al. 2003), more compulsive and complex 
repetitive behaviors (Snowden et al. 2001), heightened perception of pain and sensory 
stimuli leading to hypochondriasis, and increased sensitivity to temperature (Fletcher et al. 
2015). Cases of svPPA with altered auditory perception such as hyperacusis and persistent 
tinnitus (of central rather than peripheral origin) have also been observed (Mahoney et al. 
2011).  
 
Patients with the right temporal variant can be difficult to identify purely from a clinical 
assessment as they often have early behavioural changes and less prominent semantic 
difficulties initially (Chan et al. 2009). The key distinguishing feature of RTLA cases is early 
prosopagnosia (impaired recognition of familiar faces) (Tyrrell et al. 1990, Evans et al. 1995, 
Gainotti et al. 2003, Thompson et al. 2003, Joubert et al. 2006), but when compared with 
cases with predominant left temporal lobe atrophy, RTLA cases also report more difficulties 
with topographical memory (potentially due to right hippocampal atrophy) (Chan et al. 2009), 
and may have a more bizarre affect (Thompson et al. 2003). They also tend to have less 
insight into their disease (Thompson et al. 2003) and can develop other unusual features 
such as hyper-religiosity (Edwards-Lee et al. 1997, Chan et al. 2009). Not all RTLA patients 
will develop semantic impairment and initial studies have suggested that there are at least 
two RTLA variants: one that is the mirror analogue of svPPA with disease spread occurring 
interhemispherically to the left temporal lobe, and another with behavioural symptoms where 
atrophy spreads intrahemispherically, predominantly affecting the right frontal and parietal 
lobe (Kamminga et al. 2015).  These tend to have differing underlying pathologies as well: 
the right SD cases have FTLD-TDP Type C pathology, whereas patients with bvFTD rarely 
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have this subtype (Rohrer et al. 2011a, Lashley et al. 2015) potentially affecting accurate 
targeting of future treatments towards the different disease groups.   
NfvPPA 
Approximately 25% of patients with FTD present with nfvPPA (Johnson et al. 2005). The 
classical neuroimaging feature is atrophy of the left posterior (and inferior) frontal lobe and 
insular cortex (Rohrer et al. 2009b). In contrast to the fluent aphasia observed in svPPA, 
patients with nfvPPA have non-fluent speech, with the two core features being agrammatism 
and slow labored speech production (‘effortful speech’) (Gorno-Tempini et al. 2011). In some 
patients the former impediment is dominant, and in others, the latter, but in most cases the 
disease evolves to result in both features (Rohrer et al. 2010c). Patients with nfvPPA tend to 
present earlier than patients with svPPA, as speech is obviously disrupted and sounds 
abnormal early on (Hsieh et al. 2012). Importantly, single word comprehension and object 
knowledge are preserved, as semantic memory is intact, and this particularly helps to 
differentiate from the semantic variant in early disease (Gorno-Tempini et al. 2011). Patients 
report word-finding difficulties and do display anomia, but the anomia is less severe than 
svPPA cases. Speech agrammatism manifests as use of short, simple phrases which can 
sound muddled and ‘telegraphic’, due to omission of short connecting words and other 
function words, use of words in the wrong order, and misuse of word endings, verb tenses, 
pronouns, prepositions and conjunctions (Mesulam 2003, Rohrer et al. 2008). There is also 
difficulty in comprehending grammar, leading to impaired sentence comprehension, 
particularly if sentences are long and syntactically complex (Grossman & Moore 2005). 
Patients can develop binary word reversals (typically yes/no, or pronouns e.g. he/she) 
saying the opposite word to what they intended (Frattali et al. 2003) or utter sudden, 
unintended, stereotyped responses such as ‘don’t know’ to different questions before giving 
the correct answer (Snowden & Neary 1993).   
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Speech apraxia impairs the patient’s ability to program and plan the motor aspects of speech 
production properly, leading to effortful trial and error ‘groping’ of orofacial movements in the 
effort to produce the correct sounds (Duffy 2006, Josephs et al. 2006). Some patients 
perseverate on consonants or syllables, leading to a new ‘stuttering’ quality to speech as the 
initial presenting symptom (Kertesz et al. 2003). The variability of an apraxia of speech can 
lead to a misdiagnosis of a ‘functional stutter’ or functional speech disorder i.e. of a non-
organic basis by non-specialists, particularly as symptoms can fluctuate and become worse 
with anxiety or effort. The prosody of speech is also disrupted, thereby affecting its natural 
rhythm, rate (commonly leading to slowing), volume, or intonation (Josephs et al. 2006). 
There are typically distorted speech sounds (phonetic errors) due to errors in execution of 
programmed speech sounds, typified by syllable or consonant deletions, insertions, 
substitutions, distortions, repetitions and prolongations such as ‘capititain’ rather than 
‘captain’  (Duffy 2006, Gorno-Tempini et al. 2011), which can all make speech sound 
‘jumbled up’ to the patient and their relatives. Writing can be intact, or show grammatical 
errors later on in disease.  
 
As well as these core speech production features, the agrammatism affects language in a 
broader sense.  Repetition of single words is relatively preserved (except for more complex 
multi-syllabic words which becomes effortful), but repetition of longer sentences that are 
grammatically complex is affected. Over time speech deteriorates to a point where the 
patient has extreme difficulty making themselves understood and eventually mutism ensues, 
although this can be an early feature in some cases (Gorno-Tempini et al. 2006). Many 
patients switch to non-oral methods of communication such as writing on a notepad, or 
electronic language applications on handheld tablet computers. Orofacial/buccofacial 
apraxia, is also seen, which impairs the patient’s ability to plan oral movements, leading to 
difficulty initiating swallowing, coughing, and yawning (Tyrrell et al. 1991). On bedside 
testing, patients are unable to perform these actions to command, usually responding by 
repeating the word ‘cough’ or ‘yawn’ rather than the action itself (Tyrrell et al. 1991). Many 
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patients display limb apraxia, particularly affecting the right side. Although subtle initially, this 
often worsens, progressively impairing hand function (Mesulam 2003).   
LvPPA 
Around 30% of patients with PPA have the more recently described syndrome lvPPA 
(Kertesz et al. 2003, Gorno-Tempini et al. 2004, Rosen et al. 2006, Gorno-Tempini et al. 
2008). The hallmark imaging feature is left posterior temporoparietal atrophy encompassing 
the posterior superior temporal lobe, inferior parietal lobe, precuneus and mesial temporal 
lobe (Gorno-Tempini et al. 2004, Rohrer et al. 2013a). The syndrome is thought by some to 
be an atypical and uni-hemispheric presentation of AD (Ahmed et al. 2012, Rohrer et al. 
2012), although associated pathology is not universally ‘AD-like’ (Harris et al. 2013a, 
Mesulam et al. 2014) and it is difficult to predict based on clinical features which patients 
have underlying AD versus other pathology (Chare et al. 2014). The key clinical features of 
lvPPA are frequent word-finding pauses, anomia and impaired sentence (rather than single 
word) repetition (Gorno-Tempini et al. 2004, Gorno-Tempini et al. 2008). There is also 
preserved single word comprehension and object knowledge as semantic memory is intact, 
but impaired comprehension of longer sentences, without agrammatism or apraxia of speech 
(Gorno-Tempini et al. 2008, Rohrer et al. 2012). On speech assessment, there are frequent 
pauses (as the patient tries to retrieve the right word rather than apraxia of speech), and 
phonological errors (which are well articulated and not distorted, but definitely incorrect, such 
as ‘coptain’ rather than ‘captain’) due to difficulty with the phonology of the anticipated word. 
These phonological errors also appear in writing, and there may be a phonological dyslexia, 
affecting reading of new or nonsense words. The short-term, phonological memory deficit in 
lvPPA also characteristically impairs sentence repetition in a length-dependent manner, but 
spares single word repetition (Gorno-Tempini et al. 2008). Although comprehension of single 
words is intact, there can be difficulty in comprehending longer sentences, due to the deficit 
in phonological memory, but this is not affected by grammatical complexity like in nfvPPA. 
Patients with severe lvPPA can be difficult to differentiate from patients with nonfluent PPA. 
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However, the key differentiating features for lvPPA are lack of agrammatism, lack of apraxia 
speech, lack of orofacial apraxia, preserved prosody and impaired sentence repetition 
(Gorno-Tempini et al. 2008, Chare et al. 2014).  Limb apraxia is often present due to parietal 
involvement (Rohrer et al. 2012).    
 
Parkinsonism and motor features in PPA 
Subtle signs of parkinsonism are observed in a large proportion of patients with PPA, mostly 
in patients with nfvPPA. Typically this is on the right hand side (i.e. contralateral to 
predominant left hemispheric involvement) and leads to mild cogwheeling, bradykinesia or 
rigidity on examination when the other hand is engaged in repetitive and simultaneous 
tapping, or subtle dystonia or asymmetrical posturing of the hand when distracted (Mesulam 
2013). As disease progresses, parkinsonism can worsen and lead to a frank parkinsonian 
syndrome, most commonly with features of CBS (Graham et al. 2003, Josephs et al. 2006, 
Josephs & Duffy 2008) and less commonly PSPS (Josephs et al. 2005, Josephs et al. 2006). 
Overlap of svPPA with PSPS or CBS is rare, and if present is usually associated with 
atypical FTLD-tau pathology (Clerc et al. 2013), although parkinsonism can appear late on in 
disease (Hodges & Patterson 2007, Kremen et al. 2011). Patients with lvPPA typically do not 
develop florid parkinsonism (unless there is underlying CBD pathology).  
 
Similar to the bvFTD/MND spectrum, there are also patients with PPA that develop MND or 
clinical features suggestive of MND but not fully meeting criteria e.g. mild wasting or 
fasciculations were seen in a small proportion of patients with nfvPPA in one study (Burrell et 
al. 2011). Although most cases of PPA-MND have nfvPPA there is a subgroup of patients 
with RTLA who can rarely develop MND, typically associated with FTLD-TDP type B 
pathology and predominant lower motor neuron features (Coon et al. 2012), or prominent 
upper motor neuron signs and pathological evidence of corticospinal tract degeneration and 
FTLD-TDP type C pathology (Josephs et al. 2013). MND in typical svPPA and lvPPA is rare. 
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Some MND patients develop language impairment not fully meeting criteria for PPA. 
Detection of aphasia in the presence of dysarthria can be difficult however, so it may be 
under-reported; one recent study suggested language dysfunction in 43% of MND patients 
(Taylor et al. 2012). This needs further study, as these language difficulties will affect use of 
alternative communication methods such as electronic writing boards, in patients who have 
lost motor speech due to bulbar involvement. 
Clinical syndromes of familial FTD 
Familial FTD is observed in around a third of all FTD cases, and more commonly presents 
as bvFTD than other FTD subtypes. Mutations in MAPT, GRN and C9ORF72 are the most 
commonly identified causes of familial FTD, and in this section we summarize the clinical 
syndromes observed in these cases. We also describe the phenotype of patients with 
pathogenic mutations in rarer genes (VCP, CHMP2B, TREM2, TARDBP, FUS, UBQLN2, 
and SQSTM1) and provide an overview of clinical syndromes recently discovered to be 
associated with mutations in the gene TRAF family member-associated NF-kappa-B 
activator (TANK)-binding kinase 1 (TBK1).  A summary of the various features of the clinical 
syndromes associated with these genes is presented in Table 3. 
MAPT 
To date there have been 55 pathogenic mutations identified in MAPT. Mean age at onset is 
in the mid-fifties (Snowden et al. 2015), with a peak age at onset between 45 and 65 years. 
On average, patients present younger than those with GRN or C9ORF72 mutations, with an 
age at onset of less than 50 years in around 50% of cases (Snowden et al. 2015).  However, 
patients with MAPT mutations may have a broad range at onset from their 20s to their 80s 
(van Swieten & Spillantini 2007). Mean disease duration is 8 years (Snowden et al. 2015), 
but with a wide range of 5 to 30 years (Seelaar et al. 2011). 
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The typical clinical picture in MAPT-associated FTD is bvFTD with or without parkinsonism, 
with or without a degree of language decline (usually mild semantic impairment) later on in 
disease (Seelaar et al. 2011, Benussi et al. 2015). However, patients can present with a 
wide range of features, and there is generally poor correlation of clinical features with the 
underlying gene mutation (Benussi et al. 2015).  
 
Parkinsonism can occasionally be the sole presenting feature of disease, but more typically 
develops after onset of bvFTD (van Swieten & Spillantini 2007, Kertesz et al. 2011, Rohrer & 
Warren 2011). Parkinsonism usually manifests as bradykinesia, rigidity (limb and/or axial), 
postural instability, and poor response to levodopa (Park & Chung 2013, Siuda et al. 2014). 
However, a levodopa-responsive asymmetrical resting tremor has been observed in some 
patients (Tsuboi et al. 2002), although response is rarely sustained. Parkinsonism can be 
part of an isolated CBS (Rossi et al. 2008, Kouri et al. 2014) or less frequently PSPS (Rohrer 
et al. 2011b). Pyramidal signs, postural tremor, myoclonus, dystonia, dysarthria and 
abnormal eye movements have also been observed (Siuda et al. 2014). MND is rare, but 
lower motor neuron signs such as muscle wasting and fasciculations have also been 
reported (Zarranz et al. 2005, Di Fonzo et al. 2014). 
 
Prominent behavioural features in patients with MAPT mutations include disinhibition, 
obsessionality and stereotyped repetitive behaviors, but apathy is less common than in GRN 
or C9ORF72 cases (van Swieten & Spillantini 2007, Snowden et al. 2015). Executive 
dysfunction is well recognized in MAPT cases but does not differentiate from patients with 
GRN or C9ORF72 mutations (Snowden et al. 2015). Neuropsychiatric presentations are less 
common than in cases with GRN or C9ORF72 mutations, but are still seen: a patient with 
the S356T mutation who had been diagnosed as schizophrenia aged 27 had confirmed 
FTLD-tau at post-mortem and a family history of ‘schizophrenia’ in her father, who died aged 
42 (Momeni et al. 2010b). Semantic impairment and anomia are common later in disease, 
(Pickering-Brown et al. 2008, Rohrer et al. 2009a) and more common than in GRN cases 
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(Snowden et al. 2015).  Although a PPA presentation is much less common than in patients 
with GRN mutations (Pickering-Brown et al. 2008), a few patients have been described, for 
example, with nfvPPA associated with V363I (Munoz et al. 2007, Rossi et al. 2014) and 
G304S (Villa et al. 2011) mutations and svPPA associated with V363I (Bessi et al. 2010) and 
P301L (Ishizuka et al. 2011) mutations. A novel mutation (C291R) has also been recently 
identified in a patient with PPA-CBS who had a prominent apraxia of speech (Marshall et al. 
2015). Episodic memory loss can be prominent in some cases and has been found in 
association with profound hippocampal atrophy in patients with a R406W mutation (Tolboom 
et al. 2010), mimicking (and therefore mistakenly diagnosed as) early onset familial AD.  
GRN 
There are currently 82 pathogenic mutations described in GRN.  Mean age at onset is later 
than MAPT, between 59 and 65 years, with a range of 35 to 89 years (Gass et al. 2006, van 
Swieten & Heutink 2008, Le Ber 2013) but this can vary widely even within the same family. 
A polymorphism in the TMEM106B gene has been shown to affect age at onset in GRN 
mutation carriers (Cruchaga et al. 2011, Finch et al. 2011, van der Zee et al. 2011). Disease 
duration is similar to MAPT, with a mean of 9 years (Snowden et al. 2015) and ranges from 
3-22 years (Beck et al. 2008).  
 
The clinical picture is variable and the identified mutation correlates poorly with the clinical 
syndrome. The most common presentation is bvFTD and less commonly PPA (Beck et al. 
2008, Le Ber et al. 2008) and these two syndromes can occur within the same family. Cases 
with GRN-associated bvFTD can have a range of features as seen in sporadic bvFTD, but 
tend to have prominent apathy (Beck et al. 2008, Snowden et al. 2015) and social 
withdrawal. Between 10 to 30% of patients can present with episodic memory impairment 
(Le Ber et al. 2008), and, when combined with evidence of apraxia, dyscalculia, and 
visuospatial dysfunction secondary to early parietal atrophy, this may appear similar to AD. 
Neuropsychiatric manifestations are quite common, with patients displaying delusions, 
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hallucinations, or ritualistic and obsessive behaviors (Le Ber et al. 2008, Momeni et al. 
2010a). In contrast to MAPT and C9ORF72 cases, there is often predominant early 
language involvement or a language-only presentation. Around 10% of cases present with 
PPA, which can occasionally precede development of CBS (Baker et al. 2006, Cruts et al. 
2006). Although the phenotype of speech disturbance is often described as nfvPPA, patients 
can often have widespread language dysfunction with features that do not neatly fit into one 
of the three main PPA phenotypes, more commonly fitting in to the PPA-U (unclassified) 
group (Rohrer et al. 2010a). Patients with PPA that appears ‘mixed’ or hard to classify, 
should therefore be investigated for the presence of a family history, or other supportive 
clinical or imaging features of a GRN mutation.   
 
Extrapyramidal features are present in around 40-60% of cases with a GRN mutation, either 
just as asymmetrical parkinsonism, or as a typical CBS-like presentation with limb apraxia 
and dystonia (Kelley et al. 2009, Siuda et al. 2014). Unlike in MAPT cases, parkinsonism is 
not often an early feature, becoming evident well after bvFTD develops (Kelley et al. 2009). 
Parkinsonism does not usually improve with levodopa (Di Fabio et al. 2010), but can 
occasionally have an initial response.  
 
MND is rarely seen, although in one large study, features of MND were found in 5.4% of 
patients with a GRN mutation (Chen-Plotkin et al. 2011).  
C9ORF72 
In 2011 two groups identified a hexanucleotide repeat expansion mutation in a non-coding 
region of the C9ORF72 gene (DeJesus-Hernandez et al. 2011, Renton et al. 2011). Healthy 
individuals without the mutation usually carry 2-20 repeats on each allele. The number of 
repeats in mutation carriers is difficult to size accurately as it is so large, but most studies 
suggest patients usually possess 400-4400 repeats (Beck et al. 2013), with most possessing 
thousands. Although the minimum repeat number for disease is not clear, most consider 
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greater than 30 repeats pathogenic (Simon-Sanchez et al. 2012, Beck et al. 2013, 
Woollacott & Mead 2014). The age at onset is extremely variable, ranging from 21-83 (mean 
50) years (Hsiung et al. 2012, Majounie et al. 2012, Snowden et al. 2012). Similarly to cases 
with GRN mutations, a TMEM106B variant may also modify age at onset in C9ORF72 
expansion carriers (van Blitterswijk et al. 2014, Gallagher et al. 2014). Disease duration is 
highly variable, ranging from 1-22 years, with a mean of 8-9 years (Hsiung et al. 2012, 
Mahoney et al. 2012). Some studies have observed more rapid progression in patients with 
C9ORF72-associated FTD or MND, although slowly progressive FTD cases have been 
observed who survive for 15-20 years (Khan et al. 2012, Gomez-Tortosa et al. 2014, 
Suhonen et al. 2014), perhaps accounting for some cases previously thought to be bvFTD 
phenocopies (Rohrer et al. 2015a).  
 
The typical presentation in C9ORF72 expansion carriers is bvFTD, MND or a combination of 
FTD and MND. Prominent behavioural features include apathy, disinhibition and loss of 
empathy (Mahoney et al. 2012), although one study observed more emotional warmth in 
patients with bvFTD secondary to C9ORF72 expansions than due to MAPT or GRN 
mutations (Snowden et al. 2015).  Although many C9ORF72 bvFTD patients have food fads 
or overeating, patients appear to have a relatively absent sweet tooth compared with non-
C9ORF72 associated FTD cases (Snowden et al. 2012). Complex, unusual, repetitive or 
stereotyped behaviors are common: 59% of patients in one study displayed complex 
behavioural routines involving sorting, washing hands or cleaning (Snowden et al. 2012).  
 
Language decline appears to be rarer than in patients with GRN and MAPT mutations; 
although C9ORF72 expansions have been identified infrequently in PPA cases, including 
nfvPPA (Renton et al. 2011, Hsiung et al. 2012, Mahoney et al. 2012, Snowden et al. 2012) 
and svPPA (Renton et al. 2011, Snowden et al. 2012, Cerami et al. 2013, Josephs et al. 
2013), these have not been described in detail and the PPA phenotype of C9ORF72 
expansion cases remains unclear.  
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On neuropsychological assessment, the key findings are profound executive dysfunction, 
reduced spontaneous/propositional speech, echolalia, perseveration, impaired verbal and 
visual episodic memory, anomia, and dominant parietal deficits, particularly apraxia and 
dyscalculia (Mahoney et al. 2012, Snowden et al. 2012). Similarly to MAPT and GRN 
mutation-associated FTD, memory impairment can be a prominent and early feature 
(Mahoney et al. 2012), as can anxiety, which can lead to misdiagnosis of ‘early-onset AD’.  
An amnestic presentation has been observed in several large cohort studies of C9ORF72 
expansion carriers (Dobson-Stone et al. 2012, Mahoney et al. 2012), perhaps due to 
involvement of the parietal lobes and posterior cingulate gyrus (Irish et al. 2013). Patients 
presenting with prominent episodic memory impairment also have a later age at onset than 
those with C9ORF72-associated bvFTD (Wojtas et al. 2012, Cacace et al. 2013), which 
makes patients look even more similar to AD. In one study 2.6% of patients initially 
diagnosed with sporadic or familial AD possessed C9ORF72 expansions; confusingly all had 
AD-like biomarkers in cerebrospinal fluid (although without histopathological confirmation), 
which further complicated the diagnostic picture (Wallon et al. 2012).  
 
Psychiatric presentations are common, particularly psychosis (Arighi et al. 2012, Boeve et al. 
2012, Calvo et al. 2012, Dobson-Stone et al. 2012, Englund et al. 2012, Mahoney et al. 
2012, Galimberti et al. 2013, Kertesz et al. 2013, Devenney et al. 2014, Snowden et al. 
2015). Typical features include delusions, visual or auditory hallucinations, odd somatoform 
or tactile hallucinations, and prominent agitation and anxiety, perhaps due to altered body 
schema processing associated with cortico-thalamo-cerebellar network involvement 
(Downey et al. 2014).  Bipolar disorder and obsessive-compulsive-like presentations are also 
seen: in a study of 32 patients with FTD or FTD-MND and the C9ORF72 expansion, 38% 
had prominent psychotic features at presentation and had been diagnosed with paranoid 
schizophrenia, delusional psychosis or a somatoform psychosis (Snowden et al. 2012). 
However, cases with a C9ORF72 expansion have been only very rarely identified in 
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individuals with typical schizophrenia (0.67%) (Galimberti et al. 2014a) or bipolar disorder 
(0.5-1%) (Meisler et al. 2013, Galimberti et al. 2014b). 
 
Parkinsonism is also common and in some studies detectable in up to a third of patients 
(Boeve et al. 2012). It typically manifests as a symmetrical akinetic-rigid syndrome with gait 
disturbance, with or without a tremor that is usually postural or action, but rarely resting, in 
nature. Occasionally parkinsonism can be the sole manifestation for over 10 years, only later 
morphing into more typical bvFTD. Most patients do not benefit from levodopa. The 
expansion has also been detected in a few patients who have been clinically diagnosed with 
another neurodegenerative disorder including idiopathic Parkinson’s disease, (O'Dowd et al. 
2012, Cooper-Knock et al. 2013, Lesage et al. 2013), Lewy body dementia (Robinson et al. 
2014), multiple system atrophy (Goldman et al. 2014), PSPS (Origone et al. 2013), CBS 
(Lindquist et al. 2013), prion disease (Majounie et al. 2012, Beck et al. 2013), and 
Huntington’s disease phenocopies (Hensman Moss et al. 2014). There have been a small 
number of cases with prominent (Lindquist et al. 2013) or isolated (Corcia et al. 2015) 
cerebellar ataxia associated with the C9ORF72 expansion.   
 
All subtypes of MND have been observed in association with the expansion although adult-
onset ALS is by far the most common, and often indistinguishable from sporadic ALS 
(Cooper-Knock et al. 2012, Snowden et al. 2013). Patients with C9ORF72-associated MND 
tend to have a higher prevalence of behavioural changes and cognitive impairment 
(Millecamps et al. 2012, Montuschi et al. 2015).  
 
VCP 
In 2004, mutations in VCP on chromosome 9p13.3 were identified in cases of inclusion body 
myositis with Paget’s disease of the bone and FTD (IBMPFD), an autosomal dominant 
‘multisystem proteinopathy’ (Watts et al. 2004, Benatar et al. 2013). VCP mutations have 
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very rarely been described as causing isolated FTD (van der Zee et al. 2009). Although at 
least 19 mutations exist they account for less than 1% of cases of FTD overall (Cruts et al. 
2012). The clinical presentation tends to start with a myopathy in the fourth decade in 90% of 
cases, with subsequent cognitive decline from the fifth decade onwards in 30% of patients 
and Paget’s disease in 45%. Most patients develop bvFTD, although early semantic and 
other language deficits are also observed (Kim et al. 2011), and an MND phenotype, with or 
without FTD overlap (Miller et al. 2012, Hirano et al. 2015) is seen more rarely. Although 
parkinsonism is rare, several mutations are associated with development of an akinetic-rigid 
syndrome in later disease stages (Watts et al. 2004, van der Zee et al. 2009, Spina et al. 
2013), and rare cases present as idiopathic Parkinson’s disease with levodopa 
responsiveness (Chan et al. 2012).  
CHMP2B 
Study of a large Danish kindred with familial FTD (Skibinski et al. 2005) led to the discovery 
of the CHMP2B gene mutation on chromosome 3p11.2. Outside of this family, variants in 
CHMB2B have been identified only extremely rarely. Most cases have FTLD-UPS, 
characterized by inclusions that are positive for ubiquitin and p62 but negative for TDP-43 
and FUS on histopathological analysis of brain tissue (Holm et al. 2009). Average age at 
onset of FTD is 58 (range 46-65) years, with average disease duration of around 10 years, 
although disease often presents insidiously and can be slowly progressive. The typical 
clinical presentation is bvFTD, often with more widespread cognitive impairment, combined 
with prominent late parkinsonism (usually an asymmetrical akinetic-rigid syndrome), 
dystonia, pyramidal signs and myoclonus (Gydesen et al. 2002, Stokholm et al. 2013). MND 
has been reported in a few cases (Parkinson et al. 2006, Cox et al. 2010).  
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TARDBP 
Mutations in the TARDBP gene on chromosome 1 were initially identified in familial and 
sporadic ALS cases (Kabashi et al. 2008, Rutherford et al. 2008, Sreedharan et al. 2008, 
Van Deerlin et al. 2008), and account for 4-6% of familial ALS cases and 1% of sporadic 
ALS cases. They also account for a small proportion of cases with combined FTD-MND 
(Benajiba et al. 2009, Chio et al. 2010), associated with a broad phenotype including 
features of parkinsonism or an overlap syndrome of MND/PSPS (Moreno et al. 2015). One 
case of bvFTD with a supranuclear gaze palsy and chorea has been observed (Kovacs et al. 
2009). TARDBP mutations are very rare in pure FTD, with less than 20 cases currently 
identified; even fewer have had neuropathological confirmation of FTLD (Gitcho et al. 2009, 
Gelpi et al. 2014, Moreno et al. 2015).  FTD cases have had bvFTD or svPPA, with a wide 
range of age at onset (29-77 years) (Borroni et al. 2009, Gitcho et al. 2009, Gelpi et al. 2014, 
Synofzik et al. 2014, Moreno et al. 2015).  
SQSTM1 
Mutations in SQSTM1 (encoding for p62/sequestome 1) on chromosome 5q35 lead to 
isolated Paget’s disease of the bone (Gennari et al. 2010), which is a clinical feature also 
found in cases of multisystem proteinopathy associated with VCP-1 mutations. More 
recently, SQSTM1 mutations have also been identified in familial and sporadic MND and 
FTD-MND (Fecto et al. 2011, Rubino et al. 2012, Chen et al. 2014). However, they have 
recently been identified in a small number of patients with pure FTD without associated ALS 
(Le Ber et al. 2013, Miller et al. 2015). The clinical phenotype of FTD with underlying 
SQSTM1 mutations appears to be highly variable. The average age at onset is 60 years 
(range 48-73), with an average disease duration of 10 years (range 2-29) (Le Ber et al. 
2013). The majority of patients present with a bvFTD-like syndrome, with a third having 
concurrent Paget’s disease of the bone. In a more recent case series of 465 FTLD patients, 
four patients had SQSTM1 mutations (0.85%), all of whom presented with atypical FTD 
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syndromes including bvFTD, RTLA with prominent semantic impairment and CBS (Miller et 
al. 2015).  
FUS 
Similarly to TARDBP, FUS mutations are far more prevalent in familial ALS (4%) and 
sporadic ALS (<1%) than in FTD-MND or FTD alone (Ng et al. 2015). The first ALS-
associated mutation in FUS on chromosome 16p11.2 was identified in 2009 (Kwiatkowski et 
al. 2009, Vance et al. 2009), and was associated with characteristic FUS-positive protein 
inclusions in spinal cord neurons. However, FUS mutations are rarely seen in patients with 
FTD who have this pathology in brain tissue. Currently 4 mutations linked to FTD-MND exist 
(Blair et al. 2010, Ticozzi et al. 2009, Broustal et al. 2010, Yan et al. 2010) and 2 cases of 
pure bvFTD with a FUS variant have been reported (Van Langenhove et al. 2010, Huey et 
al. 2012).  
UBQLN2 
Originally identified in association with X-linked familial ALS, 4 further mutations in UBQLN2 
were identified in a study of another 40 patients with MND with an apparently X-linked mode 
of transmission (Deng et al. 2011). 23% of these patients had FTD-MND, usually with a 
bvFTD phenotype which occasionally preceded onset of motor symptoms, and age at onset 
varied widely (16-71 years) with a disease duration usually less than 4 years. A more recent 
study found UBQLN2 mutations in 2/161 ALS patients and 1/45 FTD patients, with all 
patients presenting with apparently sporadic disease (Synofzik et al. 2012).   
TREM2  
Mutations in the gene TREM2 on chromosome 6p21.1 were first identified in association with 
an autosomal recessive, rare condition called polycystic lipomembranous osteodysplasia 
with sclerosing leukoencephalopathy (PLOSL or Nasu-Hakola disease) (Paloneva et al. 
2000). Patients with Nasu-Hakola disease develop multifocal bony cysts, ankle swelling and 
fractures in the third decade, followed by an FTD-like cognitive decline in the fourth decade 
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and death in the fifth decade.  More recently there have been observations of patients with 
homozyogous or compound heterozygous TREM2 mutations who develop dementia without 
bony involvement (Chouery et al. 2008, Giraldo et al. 2013, Guerreiro et al. 2013a, Guerreiro 
et al. 2013c, Lattante et al. 2013, Rayaprolu et al. 2013, Le Ber et al. 2014). Patients 
developed cognitive and neuropsychiatric symptoms in their thirties to late forties, 
characterized by a frontal dysexecutive syndrome, reduced empathy, disinhibition, and 
overeating, as well as language dysfunction, episodic memory problems, parietal deficits, 
parkinsonism (mainly bradykinesia) and seizures. Death ensued by late forties or fifties in 
most cases. Heterozygous TREM2 variants have recently been described as a risk factor for 
AD (Benitez et al. 2013, Guerreiro et al. 2013b, Jonsson et al. 2013, Pottier et al. 2013) but 
studies have been mixed as to whether this is also the case for FTD (Lattante et al. 2013, 
Rayaprolu et al. 2013, Borroni et al. 2014, Cuyvers et al. 2014, Ruiz et al. 2014, Slattery et 
al. 2014, Thelen et al. 2014, Lill et al. 2015).  
 
TBK1 
Mutations in the gene TBK1 were recently identified in cohorts of MND, FTD and FTD-MND 
patients (Cirulli et al. 2015, Freischmidt et al. 2015, Gijselinck et al. 2015, Le Ber et al. 2015, 
Pottier et al. 2015). The overall prevalence of TBK1 mutations across the FTD and MND 
spectrum ranges from 0.4-4.5%, but mutations are more common in FTD-MND and rare in 
FTD alone. For example, one recent study identified a TBK1 mutation in 0.5% of patients 
with isolated MND but 10.8% of familial FTD-MND patients, although mutations were rare in 
isolated FTD (1 patient only) (Le Ber et al. 2015). In a Belgian study, loss-of-function 
mutations were identified in 1.1% (5/460) with isolated FTD, 3.4% (5/147) with isolated MND 
and 4.5% (1/22) with FTD-MND (Gijselinck et al. 2015). Dual mutations seem to be common 
including concurrent C9ORF72 expansions (Gijselinck et al. 2015) and mutations in the 
optineurin (OPTN) (Pottier et al. 2015) or FUS (Freischmidt et al. 2015) genes.  In one study 
of patients with confirmed FTLD-TDP and clinical FTD, age at onset of cognitive symptoms 
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ranged from 64 to 80 years, with an average disease duration of 5.6 years (range 2-10 
years) (Pottier et al. 2015). Clinical diagnoses of those presenting with dementia were 
heterogeneous, including bvFTD, nfvPPA, AD or FTD-ALS. In another study of seven 
patients with TBK1 mutations and FTD (one with concurrent MND), the average age at onset 
was 66.3 years (Van Mossevelde et al. 2015): five out of six cases with isolated FTD had 
bvFTD but with early episodic memory impairment as well as prominent parkinsonism 
(Gijselinck et al. 2015, Van Mossevelde et al. 2015) whilst the other case developed PPA 
aged 70 with reduced speech output, word retrieval difficulties and semantic paraphasias 
(Van Mossevelde et al. 2015). NfvPPA with prominent agrammatism has also been 
described in a patient with combined TBK1/OPTN mutations Pottier et al. 2015). Similar to 
C9ORF72 expansion carriers, a high proportion of MND cases with a TBK1 mutation (~50% 
in one study) demonstrated cognitive impairment (Freischmidt et al. 2015). Further studies in 
larger cohorts with detailed clinical phenotyping and clinicopathological correlation will be 
invaluable to clarify the spectrum of TBK1-associated neurodegenerative disease and to 
inform clinicians about which patients they should test for these mutations. 
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FTD gene 
Age at onset 
(years) 
Disease 
duration 
(years) 
Typical 
clinical 
presentation 
Prominent 
behavioural and 
psychiatric features 
Language 
impairment 
Other cognitive 
deficits 
Parkinsonism/ 
extrapyramidal 
features 
Motor neuron 
features 
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MAPT 
Mean:  
mid 50s 
Range: 20s-
80s  
Mean: 8 
Range: 5-30 
BvFTD +/- 
parkinsonism 
+/- mild late 
language 
impairment 
Disinhibition, 
obsessionality, 
stereotyped repetitive 
behaviour; less 
apathy 
 
Psychiatric 
symptoms less 
common 
Usually late semantic 
impairment and 
anomia; typical PPA 
presentation much 
less common  
Episodic memory 
impairment in  
some cases 
Common early 
on; usually 
limb/axial 
rigidity, 
bradykinesia, 
and tremor; 
poorly 
responsive to 
levodopa 
Can have frank 
PSPS/CBS 
Rare 
GRN 
Mean: 59-65 
Range: 35-89 
Mean: 9 
Range: 3-22 
Variable; 
typically  
bvFTD>PPA 
>CBS. 
  
Can mimic AD  
Apathy and social 
withdrawal 
 
Psychiatric common: 
delusions, 
hallucinations, 
obsessionality, rituals 
Common; either 
bvFTD with 
prominent early 
language impairment 
or frank PPA (e.g. 
nfvPPA or atypical 
presentation with  
PPA-U) 
Episodic memory 
impairment, 
apraxia, 
dyscalculia, 
visuospatial 
dysfunction 
(parietal) 
Common later 
on (found in 40-
60%); 
asymmetrical 
parkinsonism 
with poor 
levodopa 
response, or 
CBS-like (limb 
apraxia and 
dystonia) 
Rare 
C9ORF72 
Mean: 50 
Range: 21-83 
Mean 8-9 
Range: 1-22 
Typically 
bvFTD +/- 
MND or MND 
alone; less 
commonly 
nfvPPA 
Apathy, disinhibition, 
less sweet tooth, 
more complex 
unusual repetitive 
behaviours 
 
Psychosis and 
anxiety very 
common: odd 
delusions or 
auditory/tactile 
hallucinations; may 
mimic bipolar or 
schizophrenia 
Less common, few 
have nfvPPA/svPPA 
Early episodic 
memory 
impairment 
 
Profound executive 
dysfunction, 
impaired verbal 
and visual episodic 
memory, anomia, 
apraxia and 
dyscalculia 
 
Common (30%); 
symmetrical 
akinetic rigid 
syndrome+/- 
postural or rest 
tremor; gait 
disturbance 
 
Few cases with 
cerebellar ataxia 
Common in 
bvFTD>PPA 
cases 
 
Typically ALS 
(bulbar onset 
in >40%); PLS 
and PMA rare 
TBK1 
Mean: 65.5-72 
Range: 48-80 
Mean 7.1 
Range 2-13 
FTD-MND or 
MND alone > 
FTD alone 
 
Usually 
bvFTD, some 
cases of PPA 
Disinhibition, 
aggression, motor 
agitation, apathy 
 
Psychiatric 
diagnoses common: 
bipolar disorder, 
schizophrenia, 
alcoholism, 
depression 
bvFTD: word retrieval 
difficulties, reduced 
spontaneous speech 
 
PPA: reduced 
speech output, 
repetition difficulties, 
semantic 
paraphasias or 
nfvPPA with 
agrammatism 
Early prominent 
episodic memory 
impairment 
Very common; 
rigidity, postural 
or resting 
tremor, 
bradykinesia 
Common; 
often with FTD 
but also MND 
alone 
 
Typically ALS 
with bulbar 
onset and 
prominent 
upper motor 
neuron signs 
VCP 
FTD 
Mean: 57 
Range: 49-60 
 
Myopathy 
Mean: 42 
Range: 24-61 
Death in 
40s-60s 
Progressive 
myopathy, 
Paget’s 
disease, FTD 
in 30% 
Apathy and 
disinhibition; 
psychotic features 
seen rarely 
Aphasia and early 
semantic impairment 
common 
Episodic memory 
impairment in a 
few cases 
Rare, but can 
have late stage 
akinetic-rigid 
syndrome or 
early typical 
parkinsonism in 
some cases 
Rare, usually 
myopathy or 
IBM-like, but 
can have 
MND 
CHMP2B 
Mean: 58 
Range: 46-65 
Mean: 10  
Usually 
bvFTD; rare; 
mainly in 
single Danish 
family  
Insidious onset of 
early behavioural 
change 
Dynamic aphasia 
Limited information 
available 
Prominent late 
stage; 
asymmetrical 
akinetic-rigid 
syndrome, 
dystonia, 
myoclonus 
Rare, can be 
PMA 
TARDBP Range: 29-77 
Limited 
information 
available 
Rare in FTD 
alone, more 
common in 
FTD-MND or 
MND alone 
Variable, usually 
bvFTD/ svPPA 
Prominent semantic 
impairment in a few 
cases 
Limited information 
available 
Parkinsonism 
(including PSPS) 
seen in 
combination with 
MND 
FTD-MND and 
MND much 
more common 
than FTD 
SQSTM1 
Mean: 60 
Range 48-73 
Mean 10.2 
Range 2-29 
Rare in FTD 
alone, more 
common in 
FTD-MND or 
MND alone;  
can have 
concurrent 
Paget’s 
disease of 
bone 
BvFTD-like; some 
are atypical e.g. right 
temporal FTD with 
semantic impairment, 
or CBS-like 
Limited information 
available 
Limited information 
available 
Limited 
information 
available 
FTD-MND and 
MND much 
more common 
than FTD 
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Table 3 Summary of clinical features of familial frontotemporal dementia (FTD) syndromes. AD = Alzheimer’s disease; ALS = amyotrophic lateral 
sclerosis; bvFTD = behavioural variant FTD; CBS = corticobasal syndrome; MND = motor neuron disease; nfvPPA = nonfluent variant primary 
progressive aphasia; PMA = progressive muscular atrophy; PPA-U = primary progressive aphasia unclassified; PSPS = progressive supranuclear palsy 
syndrome; svPPA = semantic variant primary progressive aphasia. Clinical features are adapted from tables in: Rohrer and Warren (2011) and Ng et al. 
(2015). 
FUS 
Mean: 40’s to 
50’s 
Mean 2-4 
Rare in FTD 
alone, more 
common  in 
MND alone, or 
FTD-MND 
BvFTD-like 
Limited information 
available 
Limited information 
available 
Limited 
information 
available 
MND much 
more common 
than FTD 
UBQLN2 
Mean 40.6 
Range: 16-71 
Mean 3.8 
Adult ALS-
FTD or 
juvenile X-
linked ALS; 
may appear 
sporadic 
BvFTD-like, 
sometimes prior to 
motor symptoms 
Limited information 
available 
Limited information 
available 
Limited 
information 
available 
FTD-MND and 
MND much 
more common 
than FTD; 
limb/bulbar 
onset ALS 
TREM2 
Nasu-Hakola 
disease: 30s 
 
FTD-like 
syndrome: 
30s-40s 
Death in 
50s 
Homozygous 
mutations 
cause Nasu-
Hakola 
disease, or 
FTD-like 
syndrome 
without bony 
involvement. 
 
Heterozygous 
variants 
associated 
with AD 
Nasu-Hakola disease 
causes bony cysts, 
ankle swelling and 
fractures 
 
FTD-like syndrome 
with compound 
heterozygous 
mutations is bvFTD-
like; seizures and 
visual hallucinations 
also observed 
Present, including 
non-fluency, anomia, 
semantic 
paraphasias 
Episodic memory 
and parietal 
impairment 
observed 
Common; 
bradykinesia, 
postural 
instability 
Brisk tendon 
reflexes seen 
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Presymptomatic individuals 
With an increasing number of gene mutations linked to FTD, and as potential treatments for 
FTD appear on the horizon, we need sensitive and reliable biomarkers of disease for use in 
clinical trials of patients with sporadic and familial FTD. In other diseases such as AD and 
Huntington’s disease, there is evidence of change in a number of biomarkers several years 
prior to symptom onset (Scahill et al. 2002, Tabrizi et al. 2009, Bateman et al. 2012), 
suggesting that one needs to intervene well before clinical symptoms develop to significantly 
ameliorate disease. Up until now, large scale analyses of neuropsychological and 
neuroimaging biomarkers have been notably absent in both sporadic and familial FTD 
(Rohrer et al. 2013b), and there are no reliable fluid (blood, cerebrospinal fluid or urine) 
biomarkers of FTD itself, or of its underlying pathology, except for reduced serum and 
cerebrospinal fluid (CSF) progranulin levels in the majority of symptomatic patients and 
presymptomatic carriers of the GRN mutation (Finch et al. 2009, Carecchio et al. 2009). 
However, through monitoring families with FTD-associated gene mutations over many years, 
we will start to gain invaluable insights into these patterns and enable detection and 
validation of such biomarkers. Several studies have examined presymptomatic changes in 
individuals with familial FTD mutations, but most studies were on a case series basis. More 
recently, a large study of 220 individuals recruited from 11 research sites across Europe and 
Canada within the Genetic Frontotemporal Dementia Initiative (GENFI) demonstrated that 
cognitive and structural imaging changes can be detected 5-10 years before expected onset 
of symptoms (calculated from the mean familial age at onset) in adults at risk of familial FTD 
(Rohrer et al. 2015b). This study examined 118 mutation carriers (40 symptomatic: 11 with 
mutations in MAPT, 13 in GRN and 16 with the C9ORF72 expansion), 78 presymptomatic 
mutation carriers, (15 with MAPT mutations, 45 with GRN mutations and 18 with the 
C9ORF72 expansion) and 102 individuals without the mutation (‘non-carriers’). Carriers 
displayed deficits on neuropsychological assessment across a wide range of tests as early 
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as 5 years before predicted symptom onset. Deficits were particularly pronounced on tests of 
naming and executive function. There were differences between groups in which test 
detected changes the earliest: the Boston Naming Test and the Cambridge Behavioral 
Inventory-Revised (CBI-R) version showed abnormalities earliest for MAPT mutation 
carriers, the backwards Digit Span for GRN mutation carriers and the CBI-R for C9ORF72 
expansion carriers. There also appeared to be an ordered series of neuroimaging changes 
across all mutation groups prior to expected onset of symptoms. Insular atrophy was evident 
on volumetric analysis of MRI brain scans of mutation carriers 10 years before expected 
onset of symptoms, followed by temporal lobe atrophy (also at 10 years before expected 
onset), then reduced frontal lobe, subcortical, and whole brain volumes at 5 years before 
expected onset. There were also specific patterns of sequential atrophy within each group: 
MAPT mutation carriers first showed atrophy of the hippocampus and amygdala, GRN 
mutation carriers showed early insular atrophy (15 years prior to expected onset), and 
C9ORF72 expansion carriers had very early subcortical (thalamic), insular, and posterior 
cortical atrophy (25 years prior to expected onset). The long ‘run-in’ of changes prior to 
clinical onset of symptoms emphasizes the urgent need for identification and validation of 
other biomarkers of the disease process in familial and sporadic FTD, such as blood or CSF 
biomarkers, which can be measured over time.   
Current challenges and future research 
In a disease as complex as FTD, there are multiple challenges for the clinician and scientist. 
These are inherent in research studies aiming to improve our understanding of disease 
pathogenesis and disease presentation, identify novel treatments and implement better care 
for these patients and their families. However, in this section we have focused on 
summarizing challenges commonly encountered by clinicians managing patients with FTD 
and suggest future avenues for research in order to address these. 
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Diagnosis and prognosis of FTD syndromes 
Making a correct and early diagnosis is essential for both the clinician and the patient with 
FTD, as it allows access to information about current and future symptoms, likely disease 
course and avoidance of unnecessary or inappropriate treatments. As discussed above, 
there are several features of the various FTD syndromes that are also seen in other 
neurodegenerative diseases such as AD or idiopathic Parkinson’s disease and in psychiatric 
disease. In PPA, it can also be difficult to differentiate between patients with lvPPA (around 
70% of whom have AD pathology) and nfvPPA (the majority of whom have FTLD pathology).  
Patients misdiagnosed as AD, Parkinson’s disease or an atypical psychiatric syndrome may 
be offered treatment with acetylcholinesterase inhibitors, levodopa preparations or anti-
depressant or anti-psychotic medications that are at best ineffective in FTD or at worst offer 
no benefit with significant and unnecessary side effects. As well as guiding appropriate 
pharmacological treatments, a correct diagnosis allows appreciation of the support needed 
by patients with different features of FTD, for example access to a specialist speech and 
language therapist for management of PPA, or a specialist nurse with detailed knowledge of 
common practical issues or symptoms that patients and their relatives with FTD face on a 
daily basis. There are also several national support groups for patients with FTD and their 
relatives, which can be invaluable for informal advice, support and social contact.  The main 
barriers preventing correct and timely diagnosis of FTD are a lack of awareness about and 
understanding of the clinical and pathological overlap between a variety of 
neurodegenerative diseases, and the lack of available reliable biomarkers to differentiate 
between these. Some clinicians may not be aware that AD pathology can lead to a clinical 
presentation of FTD or AD, and that FTLD pathology can lead to symptoms of episodic 
memory loss in FTD, thus present like AD in a small proportion of cases.  In primary care, 
where FTD is rare, and AD is common, an AD diagnosis might have been made several 
years ago, before new symptoms prompt onward specialist referral and reconsideration of 
diagnosis.  The use of CSF biomarkers of amyloid-beta and tau, and in some centres 
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amyloid PET imaging, can be helpful in differentiating cases with underlying AD pathology. 
However, these types of biomarkers do not currently exist for FTLD pathology, and unless 
there is a known FTD-associated gene mutation, patients with FTD and prominent memory 
symptoms may still be diagnosed with AD even in the absence of definite biomarker 
evidence. Future research should elucidate biomarkers of FTD that could be used in 
combination with AD and markers of other neurodegenerative diseases to characterize these 
different syndromes more carefully.  
 
As discussed above, many of the familial FTD syndromes also include parkinsonism or 
psychiatric phenomena either early on or at some point in the disease course. This may 
occur in the context of a strong family history of psychiatric disease (which in itself is also 
common) or with seemingly ‘unrelated’ cases of MND or dementia in the family (also 
common) or, if there is incomplete penetrance of a mutation, or a small family, a complete 
absence of family history. This clinical and familial heterogeneity makes it even more difficult 
to decide if a patient has sporadic or familial FTD, and research should focus on longitudinal 
phenotyping of large cohorts of patients with sporadic and familial FTD, with varying degrees 
of family history and clinical presentations, to expand our knowledge of what could be used 
to indicate genetic risk of disease. In the current absence of consistently reliable indicators of 
familial disease (other than a known gene mutation within the family), it may be prudent to 
consider offering genetic testing to all newly diagnosed (and previously diagnosed) patients 
with FTD, particularly bvFTD and FTD-MND. 
 
Recent advances in diagnostic techniques in FTD, particularly neuroimaging, have enabled 
earlier and more accurate visual detection of FTD. There have also been significant 
improvements in recent understanding of the various patterns of atrophy across subtypes of 
sporadic and familial FTD. However, it is still difficult to categorize some patients clinically 
into which subtype of FTD they have, despite use of recently revised diagnostic criteria 
(Gorno-Tempini et al. 2011, Rascovsky et al. 2011). The key purpose of such precise clinical 
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subtyping (particularly in patients with sporadic FTD) is to predict underlying pathology and 
hence target future treatments appropriately. This is also necessary to enable accurate 
advice about disease course, predicted survival and awareness of possible new symptoms 
or diseases (for example orofacial apraxia and dysphagia in nfvPPA and risk of 
parkinsonism in FTD with MAPT mutations). A practical problem also arises in patients with 
overlap syndromes such as FTD-MND or PSPS-nfvPPA. The increasing sub-specialisation 
of neurologists, particularly in tertiary centers, means that although patients get expert care 
for each aspect of their disease, they end up with multiple appointments with more than one 
specialist (cognitive, motor nerve and movement disorder). It is not clear which model of 
care is best. Should there be multidisciplinary clinics with experts from each FTD-associated 
syndrome present? These questions about best pathways for care and patient preference 
need addressing in future research. 
 
Assessing disease severity and stage in FTD is important for guiding patient selection for 
inclusion in future clinical trials and for sensitive assessment of response to treatments in 
trials and in practice. Predicting disease onset and progression accurately is vital for 
advising patients and their relatives about prognosis, and for advising presymptomatic 
individuals who possess FTD-associated gene mutations when they are likely to develop 
symptoms. However, how best to assess disease severity is currently unclear: should it be 
through scores on neuropsychological batteries, impairment on functional rating scales, use 
of dementia staging scales currently available for use in AD, duration of symptoms, or a 
combination of these? At present, clinicians are unable to provide reliable information to 
patients about how quickly their symptoms will progress, when they will lose specific 
functions and when they might develop new behavioural, language or motor changes. In 
practice, clinicians often tend to advise that the disease is likely to continue to progress at 
the previous rate of symptom progression seen in that patient so far, but this is rather non-
specific, and not all patients will develop all features of their disease phenotype. This makes 
planning for the future very difficult and this uncertainty is likely to have a significant 
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psychological (and potentially financial) impact on patients, their carers and genetically at-
risk relatives.  If we were able to predict these milestones more accurately, this would allow 
appropriate and practical advanced decisions to be made about care and finances and 
timely introduction of currently available management strategies, such as alternative (non-
oral) methods of communication.  
 
Dilemmas in familial FTD  
Several specific challenges remain for clinicians managing patients with familial FTD and 
their relatives, and future work should be directed towards addressing these. The first 
challenge is to be able to detect presence of disease well before the onset of symptoms and 
before significant atrophy is evident on neuroimaging, and in particular to understand the 
nature and timing of the series of changes that occur.  This would enable us to predict more 
accurately when presymptomatic gene carriers will develop clinically relevant symptoms, 
intervene before this with timely treatment, and monitor for response or progression over 
time. It will also inform families with mutations like the C9ORF72 expansion, which have 
highly variable clinical features, age at onset and penetrance, about which individuals will 
develop symptoms, which symptoms are likely and at what age these may start. This will 
allow better genetic counselling of ‘at-risk’ relatives of patients with familial FTD who might 
wish to purse genetic testing, and useful advice for individuals who test positive for a gene 
mutation but are currently presymptomatic, about what lies ahead of them. In particular, 
even before successful treatments are developed, better knowledge about disease risk and 
likelihood of familial disease may encourage more individuals at risk to opt for pre-
implantation genetic diagnosis, to reduce transmission of the gene mutation in successive 
generations.  Greater awareness of the risk of familial disease within these syndromes is 
also needed across the spectrum of clinicians managing patients with FTD and MND, 
particularly for non-specialists who may feel that the absence of a family history precludes 
genetic risk. As the spectrum of neurodegenerative genes widens, there is an urgent need 
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for production of comprehensive and regularly updated guidelines for clinicians managing 
patients with potentially familial diseases, and for greater public awareness of these 
conditions.  
 
The second challenge is to understand why individuals with the same gene mutation develop 
either FTD, or MND, or both, and why some develop additional features such as 
parkinsonism or psychosis. If we understood this, it could elucidate the networks or 
pathways involved in pathogenesis of familial FTD, sporadic FTD and neurodegeneration in 
general.  
 
Finally, we should use familial FTD as a paradigm (due to a relatively good link between 
typical pathology and underlying gene mutation) for clinicopathological study to clarify the 
complex pathological heterogeneity of FTLD and understand how this leads to various 
phenotypes of clinical disease. We need to be able to correlate histopathology with disease 
course and other biomarkers of FTD so we can be more certain that any future biomarkers 
used for disease detection, monitoring or categorization in life are associated with the actual 
pathology leading to disease. This may also enable translation of biomarkers identified in 
familial disease for use in individuals with sporadic FTD, whose pathology and clinical 
presentations remain even more complex and heterogeneous than in familial FTD.  All of 
these avenues of research will be easier to pursue through collaborative studies of large 
cohorts of patients and presymptomatic individuals with familial FTD gene mutations, who 
undergo detailed phenotyping in a structured and homogeneous manner over time, such as 
within GENFI (Rohrer et al. 2015b).  
 
In summary, we have made huge progress in recent years in understanding the clinical 
heterogeneity of FTD and how it relates to its underlying molecular cause but there are still a 
number of challenges ahead for the field. As the focus of FTD research switches to the 
development of disease-modifying therapy and trials of such treatments, it will be important 
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not to forget that the study of how to improve the day-to-day care of symptomatic FTD 
patients, including finding better symptomatic medications, will need to remain a major 
research target. 
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This review clarifies the terminology of frontotemporal dementia (FTD) and summarises the 
various clinical features and most recent diagnostic criteria of sporadic and familial FTD 
syndromes. It also discusses the current major challenges in FTD research and clinical 
practice, and highlights potential areas for future research. 
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